Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase

被引:25
|
作者
Barbeau, Olivier R.
Cano-Soumillac, Celine
Griffin, Roger J.
Hardcastle, Ian R.
Smith, Graeme C. M.
Richardson, Caroline
Clegg, William
Harrington, Ross W.
Golding, Bernard T.
机构
[1] Univ Newcastle Upon Tyne, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Univ Newcastle Upon Tyne, Sch Nat Sci Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] KuDOS Pharmaceut Ltd, Cambridge CB4 4WG, England
关键词
D O I
10.1039/b705095j
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
8- Substituted 2- morpholin- 4- yl- quinolin- 4- ones and 9- substituted 2- morpholin- 4- ylpyrido[ 1,2- a] pyrimidin- 4- ones with selected aryl and heteroaryl groups as the substituent have been synthesised as potential inhibitors of DNA- dependent protein kinase. A multiple- parallel approach, employing Suzuki cross- coupling methodology, was utilised in the preparation of 8- substituted 2- morpholin- 4- yl- quinolin- 4- ones. For this purpose 8- bromo- 2- morpholin- 4- yl- quinolin- 4- one was required as an intermediate. This compound was obtained by adapting a literature route in which thermal cyclocondensation of ( 2- bromoanilino)- morpholin- 4- yl- 5- methylene- 2,2- dimethyl[ 1,3] dioxane4,6- dione afforded 8- bromo- 2- morpholin- 4- yl- quinolin- 4- one. A multiple- parallel approach, employing Suzuki cross- coupling methodology, was also utilised to prepare 9- substituted 2- morpholin- 4- ylpyrido[ 1,2- a] pyrimidin- 4- ones using 9- hydroxy- 2- morpholin- 4- yl- pyrido[ 1,2- a] pyrimidin- 4- one O- trifluoromethanesulfonate as an intermediate. 8- Substituted 2- morpholin- 4- yl- quinolin- 4- ones and 9- substituted 2- morpholin- 4- yl- pyrido[ 1,2- a] pyrimidin- 4- ones were both inhibitors of DNA- dependent protein kinase. When the substituent was dibenzothiophen- 4- yl, dibenzofuran- 4- yl or biphen- 3- yl, IC50 values in the low nanomolar range were observed. Interestingly, the pyridopyrimidinones and quinolinones were essentially equipotent with the corresponding 8- substituted 2- morpholin- 4yl- chromen- 4- ones previously reported ( I. R. Hardcastle, X. Cockcroft, N. J. Curtin, M. Desage El- Murr, J. J. J. Leahy, M. Stockley, B. T. Golding, L. Rigoreau, C. Richardson, G. C. M. Smith and R. J. Grif. n, J. Med. Chem., 2005, 48, 7829 - 7846).
引用
收藏
页码:2670 / 2677
页数:8
相关论文
共 50 条
  • [1] Developments of DNA-dependent Protein Kinase Inhibitors as Anticancer Agents
    Ma, Chen-Chen
    Li, Hui
    Wan, Ren-Zhong
    Liu, Zhao-Peng
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2014, 14 (11) : 884 - 895
  • [2] DNA-dependent protein kinase
    Jackson, SP
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1997, 29 (07): : 935 - 938
  • [3] The DNA-dependent protein kinase
    Smith, GCM
    Jackson, SP
    GENES & DEVELOPMENT, 1999, 13 (08) : 916 - 934
  • [4] DNA-dependent protein kinase
    Teraoka, H
    Watanabe, F
    SEIKAGAKU, 2000, 72 (01): : 26 - 38
  • [5] Development and therapeutic potential of DNA-dependent protein kinase inhibitors
    Hui, Zi
    Deng, Haowen
    Zhang, Xuelei
    Garrido, Carmen
    Lirussi, Frederic
    Ye, Xiang-Yang
    Xie, Tian
    Liu, Zhao-Qian
    BIOORGANIC CHEMISTRY, 2024, 150
  • [6] Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK)
    Cano, Celine
    Bailey, Chris
    Bardos, Julia
    Curtin, Nicola
    Frigerio, Mark
    Golding, Bernard
    Hardcastle, Ian
    Hummersone, Marc
    Menear, Keith
    Newell, David
    Saravanan, Kappusamy
    Shea, K.
    Smith, Graeme
    Griffin, Roger
    CANCER RESEARCH, 2010, 70
  • [7] Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)
    Clapham, K. M.
    Rennison, T.
    Rodriguez-Aristegui, S.
    Bardos, J.
    Curtin, N. J.
    Golding, B. T.
    Hardcastle, I. R.
    Newell, D. R.
    Cano, C.
    Griffin, R. J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 140 - 140
  • [8] Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK)
    Cano, Celine
    Curtin, Nicola
    Hardcastle, Ian
    Golding, Bernard
    Smith, Graeme
    Newell, Herbie
    Griffin, Roger
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [9] Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)
    Barrett, Lauren
    Rennison, Tommy
    Clapham, Kate M.
    Rodriguez-Aristegui, Sonsoles
    Bardos, Julia
    Curtin, Nicola J.
    Dennis, M.
    Finlay, Ray
    Golding, Bernard T.
    Hardcastle, Ian R.
    Newell, David R.
    Young, Gail
    Cano, Celine
    Griffin, Roger J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [10] Targeting tumor hypoxia with prodrugs of DNA-dependent protein kinase inhibitors
    Liew, Lydia P.
    Hong, Cho R.
    Dickson, Benjamin D.
    Wong, Way W.
    Jamieson, Stephen M.
    Wilson, William R.
    Hay, Michael P.
    CANCER RESEARCH, 2024, 84 (01)